Media Update, page-1605

I would generally agree with this @Onemillmin. The agreement for the 20 million rapid antigen tests not only provides a potential financial windfall for Atomo, but also fosters a cultural change in point-of-care testing; this can only be considered a win for Atomo. I look forward to the day when we see the approval of FebriDX (which has taken seemingly forever); the growth of the HIV market (we are being introduced to +135 countries); growth in the US market (via Bondi Partners, with shares opening in April 2022 at $0.40c); and registering and manufacturing of non-blood based testing (currently sitting with IP Australia).

Atomo's trajectory from mid-2020 has been buffeted by general bad luck associated with approval delays - perhaps its a marker of the medical market. Let's hope this year is different. The company certainly still has the backing of large long-term shareholders, such as Ellerston Capital, Perennial Value Management, and the Global Health Investment Fund.